Skip to Main Content

Clinical Studies and Protocols

Site Map Investigators Log-in
(MKR-0848) Behavioral and Neuroendocrine Effects of a Selective Kappa Opioid Receptor Antagonist

 Return to List of Clinical Studies
 Return to List of Protocols for Addictive Diseases
Behavioral and Neuroendocrine Effects of a Selective Kappa Opioid Receptor Antagonist

Principal Investigator:
Mary Jeanne Kreek M.D.


Contact Information:
Kimberly Lake, MSN, FNP-BC
1230 York Ave
New York, NY 10065
Telephone: 212-327-8282
Enrollment Status:
Open to Enrollment

Brief Summary of Protocol:
This study is being conducted to attempt to learn about the body’s stress hormones in healthy people and in people with addictive diseases. Stress hormones are chemicals produced in all humans in order to help the body respond to stressful situations such as illness and injury, emotional stress, and stress caused by addiction. Some of the stress hormones we are studying are: adrenocorticotropic hormone (ACTH), cortisol, prolactin, and beta-endorphin.

Detailed Description of Protocol:

What specifically makes a person eligible for the study?
You may be eligible to enter this study:

Cocaine-addicted subjects must have a past or current pattern of either daily cocaine use or 2 or more cocaine binges per week for a period of 6 months. Cannot have a current, active DSM-IV axis I disorder other than substance use disorder (e.g., major depressive disorder) as determined through clinical interview Persons currently nicotine dependent who are unable or unwilling to use a nicotine transdermal patch while a patient at RUH will not be included Cannot be HIV positive No history of seizure disorder or “conditions predisposing to seizures"



Children permitted to participate:

Potential Benefits.....
substance counseling

compensation is provided